Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study.

Cancers (Basel) · 2019 · PMC6679028 · PMID 31311148

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients presenting non-metastatic advanced HCC with vascular invasion ( n = 1136) showed a trend towards significant risk reduction with an HR of 0.78 (95% CI, 0.59–1.02) ( Figure 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.